Trial reportProceedings of the National Academy of Sciences of the United States of America2021
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Open access · greenAbstract readPragmatic Clinical TrialRandomized Controlled Trial
In one paragraph
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Pooled it
- Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.Journal of cancer research and clinical oncology · 2024Trial
- An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).Blood cancer journal · 2022Trial
- A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome.Chinese medical journal · 2026Article
- Maternal and Fetal Outcomes in Pregnant Women with Acute Leukemia.International journal of women's health · 2026Article
- Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia.Blood cancer journal · 2025Article
- [The cure for acute promyelocytic leukemia and China's contributions].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study.Blood cancer journal · 2025Article
- Review
- Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience.Hematology, transfusion and cell therapy · 2024Article
- Biochemical risk factors and outcomes of acute promyelocytic leukemia patients with thrombotic events: a matched pair analysis.Journal of thrombosis and thrombolysis · 2024Article
- Mineral crude drug mirabilite (Mangxiao) inhibits the occurrence of colorectal cancer by regulating theMedComm · 2024Article
- Natural products as potential drug treatments for acute promyelocytic leukemia.Chinese medicine · 2024Review
- Cross-sectional network analysis of plasma proteins/metabolites correlated with pathogenesis and therapeutic response in acute promyelocytic leukemia.Frontiers of medicine · 2024Article
- Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen.Clinical trials (London, England) · 2024Article
- Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy.Cancers · 2024Review
- Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia.Nature communications · 2024Article
- Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF.Blood and lymphatic cancer : targets and therapy · 2024Article
- A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 1 country.
Li ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.ORCID 0000-0003-4464-6383
Hong-Ming ZhuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.ORCID 0000-0002-2796-7102
Yan LiDepartment of Hematology, First Hospital of China Medical University, 110001 Shenyang, China.
Qi-Fa LiuDepartment of Hematology, Nanfang Hospital of Southern Medical University, 510515 Guangzhou, China.
Yu HuDepartment of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.
Jian-Feng ZhouDepartment of Hematology, Tong Ji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital of Zhejiang University College of Medicine, 310006 Hangzhou, China.
Jian-Da HuDepartment of Hematology, Fujian Medical University Union Hospital, 350001 Fuzhou, China.
Ting LiuDepartment of Hematology, West China Hospital, Sichuan University, 610041 Chengdu, China.
De-Pei WuDepartment of Hematology, The First Affiliated Hospital of Soochow University, 215006 Suzhou, China.ORCID 0000-0001-5126-9788
Jie-Ping ChenDepartment of Hematology, Southwest Hospital, Third Military Medical University, 400038 Chongqing, China.
Yong-Rong LaiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, China.
Jian-Xiang WangInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 300020 Tianjin, China.ORCID 0000-0001-9437-9151
Juan LiDepartment of Hematology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, China.
Jian-Yong LiDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, 210029 Nanjing, China.
Xin DuDepartment of Hematology, Guangdong Province People's Hospital, Guangdong Academy of Medical Sciences, 510055 Guangzhou, China.
Xin WangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, 250021 Jinan, China.
Ming-Zhen YangDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, 230022 Hefei, China.
Jin-Song YanDepartment of Hematology, The Second Affiliated Hospital of Dalian Medical University, 116027 Dalian, China.ORCID 0000-0003-4109-2602
Gui-Fang OuyangDepartment of Hematology, Ningbo First Hospital, 315010 Ningbo, China.
Li LiuDepartment of Hematology, Tangdu Hospital, Fourth Military Medical University, 710038 Xi'an, China.
Ming HouDepartment of Hematology, Qilu Hospital of Shandong University, 250012 Jinan, China.
Xiao-Jun HuangDepartment of Hematology, Peking University People's Hospital, 100044 Beijing, China.
Xiao-Jing YanDepartment of Hematology, First Hospital of China Medical University, 110001 Shenyang, China.
Dan XuDepartment of Hematology, Nanfang Hospital of Southern Medical University, 510515 Guangzhou, China.
Wei-Ming LiDepartment of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China.
Deng-Ju LiDepartment of Hematology, Tong Ji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China.
Yin-Jun LouDepartment of Hematology, The First Affiliated Hospital of Zhejiang University College of Medicine, 310006 Hangzhou, China.ORCID 0000-0003-4495-2460
Zheng-Jun WuDepartment of Hematology, Fujian Medical University Union Hospital, 350001 Fuzhou, China.
Ting NiuDepartment of Hematology, West China Hospital, Sichuan University, 610041 Chengdu, China.
Ying WangDepartment of Hematology, The First Affiliated Hospital of Soochow University, 215006 Suzhou, China.
Xiao-Yang LiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Jian-Hua YouShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Hui-Jin ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Yú ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Yang ShenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Qiu-Sheng ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Yù ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Jian LiClinical Research Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Bing-Shun WangDepartment of Biostatistics, Clinical Research Center, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.ORCID 0000-0002-0435-2543
Wei-Li ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Jian-Qing MiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Kan-Kan WangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Jiong HuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China.
Zhu ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; zchen@stn.sh.cn sjchen@stn.sh.cn ljm10378@rjh.com.cn.
Sai-Juan ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; zchen@stn.sh.cn sjchen@stn.sh.cn ljm10378@rjh.com.cn.ORCID 0000-0003-3789-1284
Jun-Min LiShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China; zchen@stn.sh.cn sjchen@stn.sh.cn ljm10378@rjh.com.cn.ORCID 0000-0002-5546-8589
Shanghai Jiao Tong University · CNSun Yat-sen University · CNFujian Medical University · CNFirst Hospital of China Medical University · CNHuazhong University of Science and Technology · CNNanfang Hospital · CNSichuan University · CNSoochow University · CNWuhan Union Hospital · CNZhejiang University · CNAir Force Medical University · CNAnhui Medical University · CNArmy Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian Medical University · CNGuangdong Academy of Medical Sciences · CNGuangxi Medical University · CNNingbo First Hospital · CNPeking University · CNQilu Hospital of Shandong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
As all-
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideConsolidation ChemotherapyCytarabineDisease-Free SurvivalFemaleHumansLeukemia, Promyelocytic, AcuteMaleMiddle AgedRemission InductionTreatment OutcomeTretinoinArsenic TrioxideCytarabineTretinoinacute promyelocytic leukemiaall-trans retinoic acidarsenic trioxideconsolidation therapyrisk stratification
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.